Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17) is a human pseudogene, meaning it is a DNA sequence that shares high sequence homology with the functional HMGN2 gene but does not produce a functional protein product. According to the HUGO Gene Nomenclature Committee definition, pseudogenes like HMGN2P17 are typically transcriptionally inactive, although emerging research suggests that some pseudogenes may have regulatory roles at the RNA level. There is little to no direct evidence that HMGN2P17 itself has a characterized biological function, is involved in cell signaling or disease as an active molecular entity, or serves as a therapeutic target. While some pseudogenes have been implicated as competitive endogenous RNAs or regulatory molecules in cancer and other diseases, there is no evidence that HMGN2P17 is a validated therapeutic or diagnostic target. HMGN2P17 may appear in databases primarily as a genomic locus or reference sequence.
None known; pseudogenes generally do not encode functional proteins, and HMGN2P17 is not a characterized molecular target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17).